Critical Cat is not “complaining.” He’s discussing a solution and supporting his proposal with facts that justify it. The only one complaining is you. You are complaining that shareholders intend to exercise their rights to obtain in formation. You are complaining that shareholders intend to exercise their rights to vote in a way that might influence the management structure of QTMM. Your are complaining that share folders are communicating with open another in a way that might allow them to benefit from each other’s information and act in concert for the good of the company and the shareholders. You are complaining that shareholders are expressing a perspective different than yours. By doing so, and by deleting posts, you are obstructive and you, PV, are the person who comes to the party with no solution and is attempting to obfuscate and obstruct and meaningful constructive action. If you were intellectually honest and morally consistent you would go back and delete 60% of your own posts.
Critical Cat is not “complaining.” He’s discussing a
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Celebrating Innovative Thought Leadership: TLFT 2025 Awards
Celebrating Innovative Thought Leadership Accenture, KPMG, and Elsevier have been honored for their groundbreaking accomplishments in thought leadership, showcasing their significant influence across brand development, social impact, and industry standards. Recognition at the TLFT 2025 Awards iResearch Services has proudly unveiled the winners of the prestigious TLFT 2025...
Continue Reading
Aquestive Therapeutics Boosts Stock Target After Event Insights
Aquestive Therapeutics made headlines back in 2024 with its stock getting a price target bump to $10 from H.C. Wainwright. This was right after they rolled out updates at a virtual investor event where they pitched their cutting-edge Adrenaverse technology. Traders were buzzing—was this the kind of news that’d drive shares up? Turns out, it was more than just fluff;...
Continue Reading
Valneva Collaborates with LimmaTech on Shigella Vaccine Study
Valneva Begins Clinical Trials for Innovative Shigella Vaccine Valneva SE, a prominent specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech firm, have recently marked a significant milestone in vaccine research. They announced the initial vaccination in a pivotal Phase 2b controlled human infection model (CHIM) study focused on their tetravalent...
Continue Reading
Innovative Vehicle Accessory Enhances Road Safety Efforts
Introducing a Revolutionary Vehicle Safety Accessory Every day, drivers encounter various challenges on the road, from navigating busy intersections to spotting pedestrians or hidden traffic signs. An innovative inventor recognized these challenges and developed the CORNER CAMERA, an inventive solution aimed at improving road safety for everyone. Understanding the CORNER...
Continue Reading
California Northstate University Celebrates Key Accreditation Milestone
California Northstate University Announces Full Accreditation California Northstate University (CNU) has achieved a significant milestone by securing full accreditation for its College of Medicine from the Liaison Committee on Medical Education (LCME). This achievement underscores CNU’s unwavering dedication to promoting educational excellence, innovation, and the...
Continue Reading